[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341797-105":59,"doc-detail-341797-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-safety-of-different-regimens-of-neoadjuvant-therapy-in-patients-with-hormone-receptor-positive-her2-negative-breast-cancer-a-network-meta-analysis","Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer - a network meta-analysis","","Systematic review and network meta-analysis assess the effectiveness and safety of multiple neoadjuvant treatment protocols for hormone receptor-positive, HER2-negative breast cancer. Searches covered Medline, Embase, Web of Science, and CENTRAL from inception to 16 January 2024, identifying randomized controlled trials and estimating pathological complete response. Seventeen RCTs with 5752 participants were included, comparing 16 regimens and evaluating adverse events, particularly grade 3-5 toxicities, across treatment combinations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-different-regimens-of-neoadjuvant-therapy-in-patients-with-hormone-receptor-positive-her2-negative-breast-cancer-a-network-meta-analysis/341797/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-different-regimens-of-neoadjuvant-therapy-in-patients-with-hormone-receptor-positive-her2-negative-breast-cancer-a-network-meta-analysis/341797.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this systematic review and network meta-analysis?","Question",{"text":112,"@type":113},"To evaluate the effectiveness and safety of different neoadjuvant treatment protocols in patients with hormone receptor-positive, HER2-negative breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the studies selected and analyzed?",{"text":117,"@type":113},"Randomized controlled trials were identified through database searches (Medline, Embase, Web of Science, CENTRAL) up to 16 January 2024, and a network meta-analysis was performed to assess pathological complete response.",{"name":119,"@type":110,"acceptedAnswer":120},"Which neoadjuvant regimens showed the best effectiveness and what was assessed for safety?",{"text":121,"@type":113},"The top regimens reported were CT(A)+olaparib, CT(A)+nivolumab, Com, CT, Mono+eribulin, and CT(A)+pembrolizumab. Safety outcomes focused on grade 3-5 adverse effects including hematological toxicity, gastrointestinal reactions, skin/mucous membrane reactions, neuropathy, hepatotoxicity, and cardiac disorders.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341797,1790538310,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Systematic Review PUBLISHED 23 August 2024  \nDOI 10.3389/fimmu.2024.1420214  \nOPEN ACCESS  \nEDITED BY Xiaowei Qi,  \nArmy Medical University, China  \nREVIEWED BY Nanlin Li,  \nAir Force Military Medical University, China Glauco Akelinghton Freire Vitiello,  \nA.C.Camargo Cancer Center, Brazil  \n*CORRESPONDENCE Weiming Liang  \n [Liangwm22@icloud.com](Liangwm22@icloud.com)[ ](Liangwm22@icloud.com)Tian Qin  \n [qintian2024kd@163.com](qintian2024kd@163.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 19 April 2024  \nACCEPTED 05 August 2024  \nPUBLISHED 23 August 2024  \nCITATION  \nWu Y, Huang S, Wei Y, Huang M, Li C, Liang W and Qin T (2024) Efﬁcacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis.  \nFront. Immunol. 15:1420214 .  \ndoi: 10.3389/fimmu.2024.1420214  \nCOPYRIGHT  \n© 2024 Wu, Huang, Wei, Huang, Li, Liang and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEfﬁcacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis  \nYongxiao Wu †, Shibo Huang †, Yanlin Wei †, Miaoyan Huang, Chunyan Li, Weiming Liang* and Tian Qin*  \nThe First Afﬁliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China  \nIntroduction: The objective of this systematic review and network meta-analysis (NMA) is to assess the effectiveness and safety of various neoadjuvant treatment protocols in individuals diagnosed with hormone receptor-positive, her2 negative(HR+/HER2-) breast cancer.  \nMaterials and methods: A systematic search was conducted in four databases (Medline, Embase, Web of Science, and CENTRAL) from the inception of the databases to January 16, 2024, to identify randomized controlled trials (RCTs) to various neoadjuvant therapy options in patients diagnosed with hormone receptor-positive, HER2-negative breast cancer. A network meta-analysis was conducted to evaluate pathological complete response (pCR) .  \nResults: There were 17 randomized controlled trials (RCTs) included in the analysis. These trials examined 16 different treatment regimens and involved a total of 5752 participants. The analysis revealed that the six most effective neoadjuvant treatment regimens for HR+/HER2- breast cancer were: CT(A)+olaparib (82.5%), CT(A)+nivolumab (76.5%), Com (74.9%), CT (72.1%), Mono +eribulin (72.0%), and CT(A)+pembrolizumab (70.4%). Paired meta-analysis for pathological complete response (pCR) found no statistically signiﬁcant distinction between treatment regimens that included both anthracycline and immunosuppressants and regimens that relied solely on anthracycline chemotherapy(OR:1 . 14, 95%ci 0 .79-1. 64, I2 = 71%, P=0 . 50) . Similarly, there was no signiﬁcant difference between platinum-based chemotherapy andanthracycline-basedchemotherapy(OR:1 . 37, 95%ci 0 .53- 3. 56, I 2 = 11%, P=0 . 52) . With regards to safety, adverse effects of grade 3-5 were observed, which included haematological toxicity, gastrointestinal reactions, skin and mucous membrane reactions, neuropathy, hepatotoxicity, and cardiac disorders.  \nConclusions: The CT(A)+Olaparib and CT(A)+nivolumab groups demonstrated superior efﬁcacy in neoadjuvant therapy for HR+/HER2- breast cancer . Furthermore, it is crucial to focus on effectively managing the adverse effects of the treatment plan to enhance patient ’s ability to tolerate it. Given the  \nFrontiers","cbCaip63fxXaXe0A","https://ap.wps.com/l/cbCaip63fxXaXe0A","pdf",3042498,15,"English","# Introduction\n## Neoadjuvant therapy and study rationale\n# Materials and methods\n## Search strategy and study selection\n## Network meta-analysis approach\n# Results\n## Included trials and treatment regimens\n## Pathological complete response findings\n## Safety and adverse events\n# Conclusions","[{\"question\":\"What is the main objective of this systematic review and network meta-analysis?\",\"answer\":\"To evaluate the effectiveness and safety of different neoadjuvant treatment protocols in patients with hormone receptor-positive, HER2-negative breast cancer.\"},{\"question\":\"How were the studies selected and analyzed?\",\"answer\":\"Randomized controlled trials were identified through database searches (Medline, Embase, Web of Science, CENTRAL) up to 16 January 2024, and a network meta-analysis was performed to assess pathological complete response.\"},{\"question\":\"Which neoadjuvant regimens showed the best effectiveness and what was assessed for safety?\",\"answer\":\"The top regimens reported were CT(A)+olaparib, CT(A)+nivolumab, Com, CT, Mono+eribulin, and CT(A)+pembrolizumab. Safety outcomes focused on grade 3-5 adverse effects including hematological toxicity, gastrointestinal reactions, skin/mucous membrane reactions, neuropathy, hepatotoxicity, and cardiac disorders.\"}]","Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer - a network meta-analysis | PDF",1790043867,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0926c8367881195b8610014b87de5822.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5f4bbe14fda5a4d138f86a7e7e0680c.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/176d2412fcdd69230537d408d93378c7.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/174a5bb6481983636efcc15b691435d2.webp",980,1385]